Objective: The objective of this study was to explore whether chronic electrocorticographic (ECoG) data recorded by a responsive neurostimulation system could be used to assess clinical responses to antiepileptic drugs (AEDs). Methods: Antiepileptic drugs initiated and maintained for ≥3 months by patients participating in clinical trials of the RNS ® System were identified. Such "AED Starts" that produced an additional ≥50% reduction in patientreported clinical seizure frequency were categorized as clinically beneficial, and the remaining as not beneficial.
Introduction
Establishing whether an antiepileptic drug (AED) is effective for an individual patient with epilepsy generally relies on patient selfreported seizures over time. However, patient and caregiver seizure reports may be inaccurate [1] [2] [3] [4] [5] . Also, depending on a patient's seizure frequency, it may take months to detect a response, and this process must be repeated with each dose adjustment. A physiological biomarker that provides a rapid assessment of a medication's effect on cortical excitability could quickly and objectively establish whether a given medication and dose are likely to be clinically effective. Chronic electrocorticographic (ECoG) sensing and recording devices could provide such information.
Pathologically increased cortical excitability is a hallmark of epilepsy [6, 7] , and AEDs measurably decrease cortical excitability. For instance, Badawy et al. [8] demonstrated that AED induced changes in transcranial magnetic stimulation-evoked measures of cortical excitability could predict seizure-freedom. This was observed regardless of the AED used. Further, Meisel et al. [9] demonstrated that the effect of AEDs could be quantified in a graded manner using intrinsic measures of cortical excitability recorded during intracranial monitoring. However, neither evoked nor intrinsic measures of cortical excitability have been available outside of the clinic or hospital.
The aim of this retrospective study was to explore whether chronic ambulatory ECoG data recorded by a closed-loop neurostimulation system (the RNS ® System, NeuroPace Inc.) could reveal potential biomarkers of cortical excitability that could be used to assess a patient's clinical response to AED changes.
Methods
The RNS ® System (NeuroPace, Mountain View CA) is a chronically implanted responsive neurostimulation system used for the adjunctive treatment of adults with medically refractory partial onset seizures arising from ≤2 seizure foci. The neurostimulator is placed within the cranium and connected to 2 leads that are placed according to that patient's seizure focus. Each lead contains 4 sensing and stimulating electrodes. The neurostimulator continually senses ECoG activity through the electrodes and is programed by the physician to detect specific patterns in the ECoG, such as epileptiform discharges or patterns characteristic of the onset of an electrographic seizure. When the neurostimulator detects one of these patterns, it responds by providing short bursts of electrical stimulation. In addition to providing responsive stimulation, the RNS System records multiple 1-to 3-minute segments of ECoG activity and provides hourly counts of physician-prespecified epileptiform events that are specific to that patient. These data are obtained as patients go about their normal routines.
Subjects
Two hundred thirty patients participated in a long-term treatment (LTT) study of the RNS System. The study protocol was approved by the institutional review boards of participating investigation sites. All patients gave written informed consent. The study was registered on www.clinicaltrials.gov (NCT00079781, NCT00264810, NCT00572195).
The study protocol has been described in detail elsewhere [10] [11] [12] . In brief, adults with medically intractable partial onset seizures with ≤2 seizure foci were initially enrolled in either an open-label feasibility or a subsequent randomized-controlled pivotal study. Safety and efficacy data were collected in each study to 2 years postimplant. Patients were then invited to continue in the open-label 7-year follow-on LTT study. The LTT study was ongoing as of the data cut-off on November 1, 2016 .
During the open-label periods of the trials, any adjustments in AEDs were documented including the AED name, dosage, date, and type of change (e.g., new medication, dose adjustment, or discontinuation). Any time patients initiated a new medication, the event was marked as an "AED Start". To be included in further analyses, AED Starts had to meet the following criteria: (1) the new AED had to be maintained for at least 3 months; and (2) the specific AED had to be started in at least 30 patients in order to provide enough data for further analysis. The AED Starts that corresponded to a resumption of a previously used medication were excluded from the analysis. Thus, individual patients could have multiple nonoverlapping AED Starts but not for the same AED.
Clinical seizure data were collected prospectively in seizure diaries. Seizure frequency was calculated based on the total number of disabling seizures, which included simple partial motor, complex partial, and secondarily generalized tonic-clonic seizures. At least 70 days of valid seizure diary data during each of the 3-month analysis periods were required for an AED Start to be included in the analyses.
Analysis timeline
Analyses were conducted over the timeframes shown in Fig. 1 . The "Before AED" period was defined as the 3 months immediately prior to initiating an AED (AED Start), the "After AED 1M " period as the first month after the AED Start, and the "After AED 3M " period as the first 3 months after the AED Start.
For all data types, comparisons were made between After AED 1M and Before AED periods (abbreviated "After AED IM :Before AED") and between After AED 3M and Before AED periods (After AED 3M :Before AED). For clinical seizure frequency data only, comparisons were also made between After AED 3M and a 3-month baseline (Preimplant Baseline) obtained prior to implantation of the neurostimulator and leads (After AED 3M :Preimplant Baseline) and Before AED and the Preimplant Baseline (Before AED:Preimplant Baseline).
Clinical seizure frequency
For assessing the effect of the individual AEDs, each patient's clinical seizure frequency was normalized to their Preimplant Baseline seizure frequency. The changes were quantified as follows: ((After AED 3M or Before AED − Preimplant Baseline) / Preimplant Baseline) * 100.
Clinically beneficial AED Starts
For changes in seizure frequency associated with AED Starts, each patient's clinical seizure frequency was normalized to their Before AED seizure frequency. The changes in seizure frequency associated with AED Starts were quantified as follows: ((After AED 3M − Before AED) / Before AED) * 100. Antiepileptic drug Starts were classified as being "clinically beneficial" when the medication change was followed by an additional ≥ 50% reduction in clinical seizure frequency, and as "not beneficial" when the medication change was followed by a b50% reduction in clinical seizure frequency.
RNS System data

Electrocorticographic events
Two types of neurostimulator hourly count data were analyzed: the number of "Detections" and of "Long Episodes". Detections consisted of times that the neurostimulator detected activity prespecified by the physician as abnormal. The Detections were mostly composed of brief interictal epileptiform events but also included a smaller number of electrographic seizure onsets. Long Episodes were abnormal events detected by the neurostimulator that did not return to baseline ECoG activity within a predefined period of time, typically 30-60 s. These often corresponded to electrographic seizures.
Only a subset of the AED Starts occurred when patients had stable Detection settings during the 4-to 6-month analysis window. For each AED Start during which Detection settings were held constant, the average hourly Detection and Long Episode rates were calculated for each of the periods: Before AED, After AED 1M , and After AED 3M . Because Detection and Long Episode settings are personalized for each patient, there was considerable variability across patients in these measures. Thus, the Detection and Long Episode rates were normalized to each patient's Before AED rate: ((After AED 1M or 3M − Before AED) / Before AED) * 100.
Electrocorticographic (ECoG) features
Electrocorticographic records stored by the neurostimulator were typically 90-180 s of 4-channel data, where each channel represents the electrographic signal sensed using a differential amplifier, bandpass-filtered at 4-90 Hz (2nd order, − 3 dB at cutoff frequency), and sampled at 250 Hz. The neurostimulator stores ECoG records based on physician-prespecified triggers such as a detected event or the time of day ("scheduled" ECoG records, which were assumed to provide a representative sample of interictal activity). The analyses used only scheduled ECoGs. Interictal activity was characterized by computing, for each scheduled ECoG record, the following features: spike rate (# of spikes/s); total spectral power (0-125 Hz); and spectral power within the delta (0-4 Hz), theta (4-8 Hz), alpha (8) (9) (10) (11) (12) , beta (12-25 Hz), low gamma (25-50 Hz), and high gamma (50-125 Hz) frequency bands. Total spectral power (0-125 Hz) and power within the individual frequency bands were estimated using Welch's periodogram method. Comparisons were made within individual frequency bands across time and within and between clinically beneficial and not beneficial AED Starts; thus, results were not influenced by filter characteristics.
Spikes were defined as in Sun et al. [13] , when the signal amplitude exceeded an amplitude threshold relative to background activity [14] . Here, the threshold was set to 7.5× the standard deviation of the background activity (σn), where σn was estimated as the median amplitude × 0.6745, with the constant 0.6745 chosen under the assumption that the amplitude of background activity was Gaussian-distributed. This heuristic for estimating the amplitude of the background signal assumes (reasonably) that spikes occupy a small fraction of the total signal and do not measurably inflate the estimate of the background activity's amplitude [15] . As reported by Sun et al. [13] , this method of spike identification using RNS System ECoG data produced comparable results with those produced using a half-wave based algorithm similar to one described by Gotman and Gloor [16] .
To ensure sufficient data for the ECoG comparisons, only AED Starts that had at least 10 scheduled ECoG records stored in each of the Before AED and After AED 3M periods and at least 5 scheduled ECoGs during the After AED 1M period were included in this analysis.
Because these analyses were intended to determine if the ECoG features could assess the response to an AED, the ECoG channel with the maximum absolute difference between each feature for the After AED 1M or After AED 3M periods compared with the Before AED period for each patient was identified. Data from this channel were then used in the group analyses for that ECoG feature. Comparisons of average ECoG feature values were made between Before AED and After AED 1M or AED 3M within the two types of AED Starts: clinically beneficial and not beneficial. For comparisons between the two types of AED Starts (clinically beneficial and not beneficial), each ECoG feature was normalized to each patient's Before AED value: ((After AED 1M or 3M − Before AED) / Before AED) * 100.
Statistics
The Wilcoxon Signed Rank test was used for paired comparisons of the percent change in clinical seizures from baseline during the Before AED period compared with the After AED period. The Wilcoxon Signed Rank test was also used for paired comparisons of the average interictal spike rate and spectral power in the Before AED and After AED periods. The Mann-Whitney U test was used for comparisons between clinically beneficial and not beneficial AED Starts including the comparisons of the percent change in Detection and Long Episode counts, interictal spike rate, and spectral power. For all assessments, the significance threshold (α) was set at 0.05.
Correlations
The correlation between the percent change ((After AED 1M or 3M − Before AED) / Before AED) * 100 for each of the different device measures (Detection rate, Long Episode rate, spike rate, and spectral power) and the percent change in clinical seizure rate ((After AED 3M − Before AED) / Before AED) * 100 was calculated using Spearman's rho, a nonparametric correlation coefficient used to measure the strength and direction of association between two ranked variables.
Logistic regression
Univariate logistic regression models were used to assess whether prior change in clinical seizure frequency with stimulation, initial AED dosage, and maximum AED dosage could predict whether the AED Start was classified as clinically beneficial or not. For all of the models, the odds ratio represented the change in odds of the AED Start being clinically beneficial.
Results
In total, there were 224 AED Starts, 193 of which had sufficient seizure diary data to be included in the analyses. These 193 AED Starts occurred in 132 patients (since an individual patient could have multiple nonoverlapping AED Starts).The AEDs initiated in the clinical trials that met the analysis criteria were clobazam, lacosamide, levetiracetam, and pregabalin. The number of AED Starts for each of the AEDs can be found in Table 1 , including the number of AED Starts occurring in subjects with seizures arising from the mesial temporal lobe, neocortical regions, and mesial temporal plus neocortical regions. Across all 4 medications, there were no statistically significant differences in the clinical response by the region of seizure onset (p N 0.05). As a result, the data from all onset region subgroups were pooled. The clinical characteristics of the 132 patients who started the new medications are provided in Table 2 .
Clinical seizure frequency
Across all medications, the median clinical seizure frequency during the Before AED period was 8 per month (range: 0-1037), and during the After AED 3M , it was 5 per month (range: 0-1050). Overall, there was an additional ≥50% reduction in seizure frequency after 30.6% (59/193) of the AED Starts; these were categorized as clinically beneficial. The AED responder rates (i.e., the percent of subjects with ≥50% reduction in seizure frequency following an AED Start) were higher for clobazam (53.7%, 22/41) and levetiracetam (51.6%, 16/31) than for lacosamide (18.8%, 18/96) and pregabalin (12.0%, 3/25). Furthermore, a significant additional median percent reduction in clinical seizure frequency was observed for clobazam (75.0% vs 42.1%; p = 0.0078) and levetiracetam (Fig. 2A) . The median and range of the initial dosage and the maximum dosage for clinically beneficial and not beneficial AED Starts for each medication are presented in Table 3 .
RNS System data
Changes in RNS System data for two representative patients who both started clobazam are presented in Fig. 2B & C. Patient 1 had an 87% reduction in clinical seizures (After AED 3M :Before AED) with the initiation of clobazam, whereas Patient 2 had a 38% increase in clinical seizures (After AED 3M :Before AED). The initiation of clobazam is followed by clear reductions in the interictal spike rate and the number of recorded Long Episodes for Patient 1 (Fig. 2B ), but not for Patient 2 (Fig. 2C) .
Electrocorticographic event data
During the Before AED period, the median Long Episode rate was 1 per day (range: 0 to 143), and the median Detection rate was 750 per day (range: 20 to 5097). Because the Long Episode and Detection rates are dependent, in part, on how the device is programed for each individual, patients with changes in the Detection and Long Episode neurostimulator settings were excluded from the analysis. In addition, all changes in these measures were normalized to the Before AED period rates and presented as a percent change. The changes in Long Episode and Detection rates were compared between clinically beneficial and not beneficial AED Starts with stable RNS System Detection settings. In both the After AED 1M and After AED 3M timeframes, clinically beneficial AED Starts were associated with a significantly greater percent reduction in the Long Episode and Detection rates (Fig. 3) .
Electrocorticographic (ECoG) features
For AED Starts with sufficient scheduled ECoG storage for analysis, clinically beneficial AED Starts showed significant decreases in interictal spike rates and total spectral power during both the After AED 1M and the After AED 3M periods compared with the Before AED period (Fig. 4A & B) . Looking within specific frequency bands, power was significantly reduced in the lower frequency bands including delta (0-4 Hz), theta (4-8 Hz), and alpha (8-12 Hz) for clinically beneficial AED Starts (Fig. 4C) . A significant decrease in power was also observed in the higher gamma (50-125 Hz) range for clinically beneficial AED Starts (Fig. 4C) . No significant changes were observed in the interictal spike rates or in the interictal spectral power for AED Starts that were not beneficial. In addition, at AED 1M there was a significantly greater percent reduction in overall spectral power (0-125 Hz) for clinically beneficial AED Starts compared with that for AED Starts that were not beneficial (Fig. 4D) . Further, at 3 months there was a significantly greater percent reduction in both interictal spike rates and overall spectral power for clinically beneficial AED Starts (Fig. 4D) . This suggests that the interictal ECoG data may also be used to distinguish between medication additions that produce clinically beneficial changes in seizure frequency and those that do not.
Correlations between device data and clinical seizure frequency
Across all AED Starts, moderate but significant correlations were observed between changes in clinical seizure frequency and changes in neurophysiological data recorded by the neurostimulator. Decreases in clinical seizure rates were accompanied by decreases in Detection and Long Episode rates as well as decreases in spike rates and overall spectral power. Most correlations were significant with p b 0.05 (Table 4 ). The relationship between the change in clinical seizure frequency and in the Long Episode rates at 1 month and between clinical seizure frequency and interictal spike rates at 3 months are presented in Fig. 5 . While there is variability between patients regarding the utility of the measures for assessing the clinical response, a relationship between the clinical response and changes in Long Episodes or in interictal spike rates can be observed. Fig. 5B and D may suggest that the relationship between the clinical response and the changes in the Long Episodes and interictal spike rates may also vary between the AEDs and dosages used.
Prior response to stimulation or AED dosage did not influence whether an AED Start would be clinically beneficial
Whether an AED Start was clinically beneficial was not influenced by the prior response to responsive stimulation, the initial dosage of the AED, or the maximum dosage of the AED. Table 5 presents the odds ratios and the associated p-value for each analysis. For each independent variable, the odds ratio was close to 1.
Discussion
Data recorded by the RNS System provided an early (at 1-3 months) indication of whether the addition of an AED was followed by a clinically meaningful reduction in seizures. At 1 month after the AED Start, there was a significantly greater median percent reduction in Detection and Long Episode rates for AED Starts that were clinically beneficial (AED Starts followed by a ≥ 50% reduction in clinical seizures) compared with those that were not. Also at 1 month, the spike rate and spectral power were significantly reduced compared with the Before AED period for clinically beneficial AED Starts only. When comparing clinically beneficial and not beneficial AED Starts, the median percent reduction in spike rate and spectral power was significantly greater for clinically beneficial AED Starts by the third month after the AED Start.
In addition, changes in Long Episode and Detection rates were significantly correlated with changes in clinically reported seizure rates by 1 month after the initiation of the medication. Changes in all neurophysiological measures were significantly correlated with changes in clinically reported seizure rates by month 3. As expected, changes in Long Episode rates had the strongest correlation with changes in clinical seizure rates. These data suggest that these measures may provide an objective assessment of cortical excitability and response to AEDs. There are limitations to the analyses of the data provided. First, the patients may have had long-term ECoG changes in response to the RNS System stimulation itself. Second, the study is retrospective and open-label. Third, the trials were not powered to provide assessments in subsets of subjects. Thus, more data will be necessary to confirm the observations made here.
Changes in electrographic event counts with AEDs
Two recent case studies have also used Detection counts recorded by the RNS System to assess hippocampal excitability in response to changes in antidepressant medications [17] and caffeine intake [18] . These studies provide further support for the observation that Detection and Long Episode rates recorded by the RNS System could provide useful objective information about cortical excitability. In addition, an initial study in a subset of patients (n = 20) has assessed the predictive value of Long Episode and Detection counts for differentiating between clinically beneficial and not beneficial AED Starts [19] . In this study, a 20% decrease in Long Episode counts within the first week after starting a new AED was shown to predict clinical efficacy with a positive predictive value of 100% and a negative predictive value of 78.6% [19] . In contrast, there were no changes in Detection counts associated with the medication change. It will be important to extend this work to a larger clinical dataset and to perform similar analyses with the interictal spike rate and spectral power data. Although these studies suggest a relationship between clinical seizures and physiological events, further validation will be important to determine the utility of Detections and Long Episodes for monitoring cortical excitability. There is variability in the utility of these measures for individual patients. This variability may, in part, be dependent on how Detection parameters are set for each individual patient's electrographic activity, which is currently a manual process involving the individual's clinical care team. There may also be variability in the utility of the measures based on the specific AED and dosage used; however, this will require further investigation with a larger sample size.
Changes in interictal spike rates and spectral power with AEDs
Continuous ECoG has been used in the epilepsy monitoring unit (EMU) to show that phase synchrony, an intrinsic measure of cortical excitability, could be used to predict clinical response to AED changes [9, 20] . In the current study, spike rate and spectral power were extracted from intermittently stored 90-to 180-second scheduled ECoG segments. These short segments of interictal ECoG activity were sufficient to see changes in the neurophysiological features associated with the addition of new AEDs. It remains to be seen if spike rate and spectral power can provide a graded measure of AED response, as has been demonstrated for phase synchrony in ECoG recordings obtained in the EMU.
While the relationship between interictal spikes and seizures is thought to be complex [21] [22] [23] [24] [25] [26] [27] [28] , Karoly et al. [29] demonstrated that interictal spikes and seizures had similar circadian patterns. They concluded that spikes may be a good marker of cortical excitability. An initial analysis of RNS System data suggests that the majority of subjects had a significant positive correlation between spikes and clinical seizures. However, there were some subjects for whom the correlation was negative [30] . This type of individual patient variability was also observed in the current study. Thus, there may be individual patient variability in terms of which ECoG feature recorded by the RNS System will be the most valuable for providing an objective assessment of disease severity and will be predictive of clinical response to treatment. In addition, as mentioned previously, the specific AED and dosage may influence the changes observed in the ECoG features.
Reductions in background or interictal ECoG spectral power have not been clearly associated with AED treatment with different effects being reported by different studies and for different AEDs [31] . For instance, one study reported that the addition of levetiracetam was associated with decreased delta and theta power and increased alpha and beta band activity [32] . However, another study noted a decrease in power (delta through gamma frequencies) accompanying the reduction of AEDs during intracranial monitoring [33] . Other studies found minimal effects of AEDs on background EEG activity [34] . While some of the reported differences are likely due to the mechanism of action of the specific AED, some of the reported differences could be related to the region from which electrophysiological recordings are obtained (e.g., within or outside of the seizure focus or the specific brain region) as well as the recording methodology (e.g., intracranial versus scalp), and whether the recordings are associated with a specific cognitive or behavioral task.
A study by Desai et al. [35] assessed the changes in chronic ambulatory ECoG activity over time as a function of their clinical response to brain-responsive stimulation. Decreases in overall power (1-125 Hz) and in gamma power (50-125 Hz) were associated with reductions in clinical seizure frequency following responsive stimulation for patients with seizures arising from the neocortex. For patients with mesial temporal lobe onsets, clinical improvements were associated with decreases in interictal spike rate and delta power (1-4 Hz). In the present study, the analyses were conducted without differentiating between patients with mesial temporal or neocortical onsets because of the sample size. Still, across all subjects, decreases in overall spectral power (1-125 Hz) and in power in the lower frequency bands (delta, theta, and alpha as well as in gamma; 50-125 Hz) were associated with clinically beneficial AEDs. Some of the observed changes in spectral power could be related to reductions in interictal spike rates. However, Desai et al. [35] observed reductions in spectral power, without changes in interictal spike rates, in patients with seizures arising from the neocortex. Future studies should assess the impact of AEDs on spectral power by region of onset.
It should also be noted that AED-associated decreases in overall spectral power and power in specific frequency bands can be related to the sedating or cognitively impairing effects of the medications [36] . For instance, diazepam decreases power in the delta through beta bands during visual sustained attention task responses [37] . Thus, it will be important to assess the relationship between AED-associated changes in these interictal ECoG features and specific side effects of AEDs.
Potential interactions between responsive neurostimulation and AEDs
The current study also suggests that patients treated with responsive stimulation were more likely to experience additional reductions in seizures when starting specific AEDs. Clobazam and levetiracetam AED Starts were associated with higher responder rates than lacosamide and pregabalin. In addition, clobazam, levetiracetam, and lacosamide were associated with a significant additional reduction in clinical seizure frequency while pregabalin was not. Although the patients who started pregabalin had a low median reduction in seizure frequency before starting pregabalin, across all AED Starts, the response to stimulation before the start of the AED did not predict the response to the AED. In other words, AED Starts that were clinically beneficial were not limited to the subset of subjects that responded to stimulation. In addition, the clinical response to the medication did not appear to be related to either the initial dosage or the maximum dosage of the new medications as these were similar for AED Starts that were clinically beneficial and those that were not.
Synergistic and antagonistic interactions between medications and stimulation have been noted with implantable cardiac defibrillators [38] [39] [40] . For instance, sodium channel blockers increase the defibrillation threshold [38] [39] [40] . Moreover, neuromodulatory therapies like responsive stimulation may result in changes to the brain that could alter the response to different AEDs. This could occur if stimulation altered the number or affinity of receptors for specific AEDs. For example, in a rodent model of pharmacoresistant epilepsy [41] , 1 Hz hippocampal stimulation resulted in an increase in the hippocampal expression of synaptic vesicle protein 2A, the binding site for levetiracetam. Testing for interactions between medications and responsive stimulation is further complicated by the fact that the majority of RNS® System patients were on multiple AEDs [10, 12] , and AEDs may interact with each other. For instance, some studies [42] , but not all [43, 44] , have suggested that the efficacy of lacosamide is better in patients who are not on other concomitant sodium channel blockers. Understanding the interactions between stimulation and AEDs could result in better outcomes for patients with epilepsy treated with both modalities.
Conclusions
In conclusion, there are significant quantitative changes in the ECoG data recorded by the RNS System following clinically beneficial AED Starts, but not for those that were not beneficial. This suggests that these data, notwithstanding individual patient variability, may be used to quickly provide useful information when assessing whether a patient may have a favorable clinical response to a new AED and may be used to supplement patient clinical reports.
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